EDESA BIOTECH INC EDSA 深 滬
交易中 10-29 11:18:18 美东时间
2.13
-0.030
-1.39%
華盛通- 最 高2.18
- 今 開2.04
- 成交量 26.01万股
- 最 低 2.00
- 昨 收 2.16
- 總市值 1495.84万
- 52周最高 4.4899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.55
- 委 比 -60.00%
- 總股本 702.27万
- 歷史最高 133.70
- 量 比 0.34
- 振 幅 8.33%
- 歷史最低 1.55
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Edesa Biotech announced positive Phase 3 results for paridiprubart in treating ARDS, showing a 25% relative reduction in mortality risk and a 41% higher rate of clinical improvement. The drug met primary and secondary endpoints, demonstrated durable survival benefits, and was well-tolerated. It has potential for standard-of-care treatment in ARDS and chronic respiratory conditions, supported by funding from the Canadian government.
10-28 11:45
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their on...
10-28 07:50
Edesa Biotech Amends Agreement with Canadian Government
Edesa Biotech ( ($EDSA) ) has issued an announcement. On September 30, 2025, Ed...
10-01 04:27
Edesa Biotech Launches At-The-Market Offering Program
An announcement from Edesa Biotech ( ($EDSA) ) is now available. On September 9...
09-10 05:00
氪星晚报 ｜霸王茶姬正式进入菲律宾市场；宇树科技宣布将在四季度提交IPO申请；金价迭创新高，多家黄金企业半年净利润翻倍
大公司： “应帆科技”完成亿元A轮融资 36氪获悉，9月1日，“应帆科技”宣布完成亿元级战略A轮融资。此轮投资人涵盖政府产业引导基金、多元产业投资机构，以及科技...
09-02 21:04
三店同开，霸王茶姬正式进入菲律宾市场
日前，霸王茶姬在菲律宾的三家门店同时开业，首次进入菲律宾市场。据了解，这三家门店分别位于SM North EDSA、Robinsons Galleria和...
09-02 16:20
霸王茶姬联手蓝海资本，追加投资加速全球化布局
（来源：辰珵） 三店齐开，文化出海提速，中国新茶饮迈向全球化新阶段 【2025年8月，马尼拉讯】—— 继凤凰网报道的霸王茶姬与蓝海资本战略合作后，双方再次释放...
08-24 06:16
Edesa Biotech Advances Vitiligo Treatment Amidst Steady Financial Performance
Edesa Biotech ( ($EDSA) ) has provided an announcement. Edesa Biotech reported ...
08-09 07:02
Edesa Biotech Q3 EPS $(0.25) Beats $(0.29) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 51.92 percent increase over losses of $(0.52) per share from the
08-09 04:36
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
Edesa Biotech reported Q3 and Q9 2025 financial results, advancing manufacturing for its EB06 candidate in vitiligo with plans to submit IND data by end-2025. CEO Par Nijhawan highlighted EB06's favorable safety profile and potential benefits for patients with extensive vitiligo. Financially, operating expenses remained stable, with a slight decrease in R&D costs offset by increased EB06-related expenses. Net loss for Q3 and Q9 2025 was $1.7M and...
08-08 20:35
